Curidium Medica plc ("Curidium" or the "Company")
CURIDIUM JOINS THE PERSONALIZED MEDICINE COALITION
London, UK, 1 August 2007, Curidium Medica plc, (LSE: CUR), the
personalized medicine company focused on bringing the right drug to the
right patient, today announced that it has joined the US-based
Personalized Medicine Coalition (PMC).
The PMC was publicly launched in November 2004 by more than a dozen
leading pharmaceutical, biotechnology, diagnostics and information
technology companies, along with major academic centers and governmental
agencies. An independent, non-profit group dedicated to advancing the
understanding and adoption of personalized medicine concepts and products
for the benefit of patients, it represents over 100 members. The
Coalition seeks to promote discussion and understanding that will lead to
the development of sound public policy on matters that affect the
realization of personalized medicine.
"The PMC has become the key organization in shaping US public policy on
personalized medicine. We believe the PMC will be instrumental in making
personalized medicine a reality," said Anne Bruinvels, CEO of Curidium
Medica. "We are very pleased to be a member of a group that will
dramatically impact the treatment of patients in the future."
Edward Abrahams, Executive Director of the PMC, welcomed the addition of
the UK-based personalized medicine company focused on psychiatric
disorders. "Schizophrenia and bipolar disorder are indications that
would benefit greatly from improved diagnostics and more targeted therapies.
We look forward to Curidium's involvement in the PMC's activities."
For further information please contact:
Anne Bruinvels +44 (0) 20 7554 8790
CEO, Curidium Medica plc
Rob Smith +44 (0) 20 7554 8793
Finance Director, Curidium Medica plc
Rhodri Cruwys / Romil Patel +44 (0) 20 7448 4400
Blue Oar Securities Plc
Billy Clegg / Edward Westropp / Anna Keeble + 44 (0)20 7831 3113
Financial Dynamics
Notes to Editors
Curidium Medica
Curidium is a personalized medicine company identifying targeted
medicines and companion diagnostics to treat patients more effectively.
Curidium's initial focus on diseases of the Central Nervous System has
resulted in the identification of a blood diagnostic test, PsychINDx(TM),
which classifies patients with schizophrenia/bipolar disorder into four
subgroups. PsychINDx(TM) may have the potential to improve the
treatment of schizophrenic/bipolar disorder patients and may support
the development of new drug treatments targeted for the different
patient subgroups.
Many chronic human diseases are heterogeneous and their patient
populations consist of mixed subgroups. Through the use of its
proprietary analysis tool, Homomatrix(R), Curidium aims to reveal
different patient subgroups characterized by distinct underlying disease
mechanisms potentially leading to the identification of:
1) Diagnostics for better identification and treatment within
heterogeneous disease populations,
2) Improved therapies identified through novel drug targets
3) Personalized medicines using companion diagnostics and targeted
treatments.
Curidium aims to continue to use this approach to improve patient
treatments in a variety of therapeutic areas.
Further information on Curidium can be found at the Company's website:
www.curidium.com.
About the Personalized Medicine Coalition
The Personalized Medicine Coalition (PMC), representing a broad spectrum
of academic, industrial, patient, provider, and payer communities, seeks
to advance the understanding and adoption of personalized medicine
concepts and products for the benefit of patients. For more information
on the Personalized Medicine Coalition, please visit
www.personalizedmedicinecoalition.org.
Curidium Medica plc (c) 2002-2007. All rights reserved.
Hamilton House, Mabledon Place, London WC1H 9BB, United Kingdom.
Email: info@curidium.com Tel.: +44 (0)20 7554 8790,
Fax: +44 (0)20 7554 8791
This information is provided by RNS
The company news service from the London Stock Exchange
CURIDIUM MEDICA PLC ANNOUNCES RE MEDICINE COALITION
| Source: Curidium Medica PLC
London--(Marketwire - August 1, 2007) -